Health News Releases

October 17, 2019 11:25

Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by India.

Utilizing the capability of one’s own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved way for a

October 17, 2019 10:45

Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CF™ 1)

Boehringer Ingelheim today announced the first patient enrolled in its Phase II clinical trial BALANCE-CF™ 1 to evaluate a new potential treatment for cystic fibrosis.[1,2] The trial will investigate

October 16, 2019 13:33

Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019

Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it

October 15, 2019 16:23

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharm

October 15, 2019 09:29

Analysis of Patients With Prior Gastrectomy Treated With LONSURF® (trifluridine/tipiracil) Published in JAMA Oncology

Servier and its partner Taiho Oncology, Inc. (US), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today that detailed results from the analysis of patients with prior gastrectomy en

October 11, 2019 11:41

Perspectum announces partnership with Precious Medical Centre

Perspectum, the leading provider of diagnostic solutions for metabolic disease and cancer, is partnering Precious Medical, a premier imaging centre in Singapore, following a successful launch event th

October 10, 2019 17:26

Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis

Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigat

October 10, 2019 16:44

National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System

Bioventus, a global leader in orthobiologic solutions, has received notice from the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG1

October 10, 2019 11:02

ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future

ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas - showcasing a number of concept technologies, including a mobile YuMi® robot, whi

October 10, 2019 10:48

Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Regis

October 04, 2019 19:25

MPEG LA Announces Peer Reviewed Article Featured in Nucleic Acid Therapeutics

World technology licensing leader MPEG LA today announced publication of a peer reviewed article in the October 2019 issue of Nucleic Acid Therapeutics on MPEG LA’s proprietary Increscent Therapeutics

October 01, 2019 16:37

New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes

Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olod

October 01, 2019 16:29

Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio

Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refrac

October 01, 2019 12:05

Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in pa

September 30, 2019 15:43

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases[1]

Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline

September 27, 2019 11:13

Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress

Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients wi

September 27, 2019 10:47

New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel investigational compound TAK-925, a selective orexin ty

September 26, 2019 11:13

First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizuma

September 25, 2019 09:12

New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has published results of a Phase 2, randomised, 12-week, open-label study

September 24, 2019 10:28

Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier Indication of Anemia and the Impact of Anemia on Patient Outcomes

Masimo (NASDAQ: MASI) announced today that in a study published in Injury, researchers used Masimo SpHb® - noninvasive, continuous hemoglobin monitoring - to investigate possible delays in the detecti

September 23, 2019 16:09

Patient Safety Leaders and Advocates Discuss Solutions to Eliminate Preventable Patient Deaths

On the same day the World Health Organization (WHO) designated World Patient Safety Day, The Patient Safety Movement Foundation’s (PSMF) Midyear Planning Meeting (MYPM) brought together more than a hu

September 23, 2019 14:08

Takeda Recognized in the 2019 Dow Jones Sustainability World Index

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average o

September 23, 2019 13:56

Larger, healthier, more plentiful — Study proves House Wellness Foods’ Feed LP20® improves stock at the cellular level.

Eons ago, the progress of humankind was thrust forward with the development of farming. Today that progress is challenged simultaneously by climatic and socioeconomic forces, and the future hangs in t

September 23, 2019 13:10

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with

September 20, 2019 13:55

Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment

There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devic

News by Region

News by Industry